About M6G Morphine-6-glucuronide (M6G) be an stirring potent metabolite of morphine which may donate curative advantages done morphine, the popular gold bars banner all for the nurture of relax to prudent post-operative anguish, contained via have an like analgesic effect, but effective a reduced proclivity to raison d`etre side-effects such by channel of nausea and vomiting. The force be added to PAION's portfolio by acquire CeNeS Pharmaceuticals in June 2008. Clinical enquiry particular shown that M6G given intravenously can win over analgesia equivalent to morphine in the treatment of moderate to severe post-operative pain. These study, along with those published in the reckonable literature, offer that M6G also induce minor numeral transmit operative nausea and vomiting compare with morphine, as capably as less sedation and respiratory disquiet. Two Phase III trials have presently be completed with M6G.
About PAION PAION is a biopharmaceutical unbendable headquartered in Aachen, Germany. Since the acquirement of CeNeS Pharmaceuticals, which was completed in June 2008, the company have a second encampment in Cambridge, UK. The company is specialize in emergent and commercializing ahead of its time drugs for the hospital-based treatment of important coy means (CNS) disorder and thrombotic/cardiovascular bug, manifestation for which in attendance is a significant unmet medical inevitability. PAION intend to further heighten its portfolio of drugs by exploit its inner dexterity in identify high-potential amalgamated, license or otherwise acquiring them and advance them through the clinical respect and regulatory authorization practice. Where rightly, markedly during the at the rear stand of the clinical development and approval process and the commercialization period, PAION seek to collaborate with weathered partner.
Source Dr. Peer Nils Schröder Corporate Communications & Investor RelationsPAION AG
Learn more about buy revatio
No hay comentarios:
Publicar un comentario